The aforementioned results suggested that immune checkpoint inhibitors or immune checkpoint inhibitors combined with endocrine therapy may achieve better results for patients with prostate cancer and a high-risk score, while for CRPC patients, CTLA-4 inhibitors or CTLA-4 inhibitors combined with endocrine therapy may prolong the survival of patients with a high-risk score. The gene discussed is CTLA4; the disease is prostate carcinoma.